Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

LINCOLN PHARMACEUTICALS LTD. - 531633 - Closure of Trading Window

 Pursuant to the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time, and the Company''s Code of Conduct for Prevention of Insider Trading, it is hereby informed that the Trading Window for dealing in the Company''s Securities shall remain closed from February 24, 2020 and shall reopen after the expiry of 48 hours from the conclusion of Board Meeting for Designated Persons viz. Directors, identified Employees, KMPs, Promoter and Promoter Group of the Company and its subsidiaries including Immediate Relatives of the Designated Persons of the Company and its subsidiaries and for the Connected Persons.
24-02-2020
Bigul

LINCOLN PHARMACEUTICALS LTD. - 531633 - Record Date For Interim Dividend

 Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and any other applicable SEBI Regulations, we wish to inform you that a meeting of Board of Directors of the Company will be held on Thursday, February 27, 2020 at the Registered Office of the Company inter-alia to consider followings: 1. To Consider and Declare Interim Dividend to the Equity shareholders for the Financial Year 2019-2020. 2. The Interim Dividend, if declared, shall be paid to the Equity Shareholders of the Company whose names appear on the Register of Members of the Company or in the records of the Depositories as beneficial owners of the shares as on Friday, March 06, 2020, which is the Record Date fixed for the purpose. 3. Any other business with the permission of the Chairman, if any.
24-02-2020
Bigul

LINCOLN PHARMACEUTICALS LTD. - 531633 - Board Meeting Intimation for Consider And Declare Interim Dividend

 LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/02/2020 ,inter alia, to consider and approve Interim Dividend to the Equity shareholders for the Financial Year 2019-2020. and The Interim Dividend, if declared, shall be paid to the Equity Shareholders of the Company whose names appear on the Register of Members of the Company or in the records of the Depositories as beneficial owners of the shares as on Friday, March 06, 2020, which is the Record Date fixed for the purpose. & Any other business with the permission of the Chairman, if any.
24-02-2020
Bigul

Lincoln Pharmaceuticals Ltd - 531633 - Standalone And Consolidated Un-Audited Financial Results For The Quarter And Nine Months Ended On December 31, 2019.

 Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith Standalone and Consolidated Un-Audited Financial Results for the Quarter and Nine Months Ended December 31, 2019, as reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held today i.e. on February 13, 2020. We also enclose herewith copies of Limited Review Report by Auditors of the Company on Standalone and Consolidated Un-Audited Financial Results for the Quarter and Nine Months Ended December 31, 2019 and Financial Highlights for the said quarter.
13-02-2020
Bigul

Lincoln Pharmaceuticals Ltd - 531633 - Outcome Of Board Meeting

 pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith Standalone and Consolidated Un-Audited Financial Results for the Quarter and Nine Months Ended December 31, 2019, as reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held today i.e. on February 13, 2020. We also enclose herewith copies of Limited Review Report by Auditors of the Company on Standalone and Consolidated Un-Audited Financial Results for the Quarter and Nine Months Ended December 31, 2019 and Financial Highlights for the said quarter.
13-02-2020
Bigul

Lincoln Pharmaceuticals Ltd - 531633 - Board Meeting Intimation for Inter-Alia To Consider And Approve The Un-Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Nine-Months Ended On December 31, 2019 Along With Any Other Business, If Any.

 LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2020 ,inter alia, to consider and approve We would like to inform that the Meeting of the Board of Directors of the Company is scheduled to be held on Thursday, February 13, 2020 at the Registered Office of the Company inter-alia to consider and approve the Un-Audited Standalone and Consolidated Financial Results of the Company for the Quarter and Nine-Months Ended on December 31, 2019 along with any other business, if any.
06-02-2020
Bigul

LINCOLN PHARMACEUTICALS LTD. - 531633 - Shareholding for the Period Ended December 31, 2019

 Lincoln Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2019. For more details, kindly Click here
17-01-2020
Bigul

Lincoln Pharmaceuticals Ltd - 531633 - Statement Of Investor Complaints For The Quarter Ended December 2019

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- MAHENDRA G PATELDesignation :- Director
13-01-2020
Bigul

Lincoln Pharmaceuticals Ltd - 531633 - Closure of Trading Window

 Pursuant to SEBI [Prohibition of Insider Trading] Regulations, 2015 read with SEBI [Prohibition of Insider Trading] [Amendment] Regulations, 2018 and Code of Practices & Procedures for Fair Disclosure of Unpublished Price Sensitive Information adopted by the Company it is informed that the Trading Window for dealing in securities of the Company shall remain closed from January 01, 2020 till 48 hours after the declaration of Financial Results of the Company for the Quarter and Nine Months Ended on December 31, 2019. During the aforesaid period when the Trading Window is closed, Directors, Senior Management Personnel, Promoter and Promoter Group of the Company and its subsidiaries including their Immediate Relatives and other Connected Persons shall not trade in securities of the Company.
31-12-2019
Bigul

LINCOLN PHARMACEUTICALS LTD. - 531633 - Result For The Quarter And Six Months Ended September 30, 2019.

 Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby enclose related party transactions, on consolidated basis, drawn in accordance with applicable Indian Accounting Standards, for the Half Year Ended September 30, 2019.
09-12-2019
Next Page
Close

Let's Open Free Demat Account